The Role of miR-326 in Adipogenic Differentiation of Human Adipose-Derived Stem Cells by Targeting C/EBPα in vitro.
Feng Y., Zhou L., Peng Y., Yang Y., Fan T., Jiang X.
Laboratory Study, published in Anat Rec (Hoboken) (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Anat Rec (Hoboken) (2019)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 31595632
- DOI
- 10.1002/ar.24281
- Citations
- 12
Abstract (original English)
The CCAAT-enhancer-binding protein α (C/EBPα) plays an important role in adipogenic differentiation of adipose-derived stem cells (ASC). Recent studies have shown that microRNAs (miRNAs) participate in the regulation of self-renewal, proliferation, and multi-directional differentiation of ASCs. In the present study, we analyzed the targeting miRNAs on C/EBPα and found that miR-326 played an essential role in it. The results of qPCR confirmed that the expression of miR-326 was reduced in adipogenic differentiation. In addition, the dual-luciferase reporter assay system verified binding between miR-326 and the 3' untranslated region of C/EBPα. Furthermore, transfection of miR-326 into human adipose-derived stem cells caused a significant reduction in C/EBPα. Our results highlight the importance of miR-326 in adipogenic differentiation and provide a reliable basis for clinical treatment of adipose-related diseases. Anat Rec, 2019. © 2019 American Association for Anatomy Anat Rec, 303:2054-2060, 2020. © 2019 American Association for Anatomy.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.